news
New Type 2 diabetes drugs may improve insulin sensitivity
Scientists have used advanced computer modelling and lab techniques to design potential new diabetes drugs that improve insulin sensitivity.
List view / Grid view
Molecular Targets
news
Pitavastatin identified as potential treatment for triple-negative breast cancer
A commonly prescribed cholesterol-lowering drug, called pitavastatin, could be used to treat patients with triple-negative breast cancer, after researchers found that it has the ability to block a key cancer survival protein.
news
TRPM5 protein switch discovery could lead to new diabetes drugs
Northwestern University scientists have discovered a hidden ‘control switch’ in the TRPM5 protein, which helps regulate taste, blood sugar and gut health and could lead to new therapies for targeting diabetes and obesity.
news
Scientists discover potential therapy for pancreatic cancer-induced cachexia
University of Houston researchers have identified a key cellular pathway involved in muscle wasting caused by pancreatic cancer, offering new insights into potential therapies.
news
Inhibiting DDR1 pathway helps breach pancreatic cancer’s drug barrier
Scientists in Japan have identified a way to weaken the dense fibrotic barrier that prevents drugs from penetrating pancreatic tumours – a promising new strategy that could improve treatment for pancreatic cancer.
article
Protein folding interference: a new path to hard-to-drug targets
Protein folding interference offers access to targets long considered unreachable by traditional drug discovery. By acting on transient folding intermediates, this approach presents a new opportunity to eliminate disease-driving proteins.
article
Logic-gated DARPins show targeted T-cell activation in tumours
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
news
MYC inhibitor Omomyc boosts PARP drug response in breast cancer
A preclinical study led by VHIO reveals that the MYC inhibitor Omomyc enhances the effectiveness of PARP inhibitors, offering a potential new treatment strategy for patients with drug-resistant triple-negative breast cancer.
news
Researchers identify new drug site on epilepsy target SV2A
A team led by St. Jude Children’s Research Hospital and UT Southwestern has mapped how key anti-epilepsy drugs latch onto their neural target, SV2A.
news
Kidney fibrosis linked to overactive Hippo signalling pathway
Scientists have used human stem cell–derived kidney organoids to uncover how abnormal Hippo signalling drives scarring in nephronophthisis, a rare genetic kidney disease.
news
Kinase inhibitors shown to accelerate protein breakdown
A new study has revealed that many kinase inhibitors – key drugs used in cancer and other diseases – also trigger the accelerated degradation of their target proteins, which could inform future therapies.
news
Targeting p300 may boost immunotherapy in kidney cancer
Researchers have discovered how renal medullary carcinoma cells evade immunotherapy by mimicking immune cells, driving rapid tumour progression.
news
Samsung invests in Phrontline to advance next-gen ADC therapies
Samsung Life Science Fund has made a strategic equity investment in clinical-stage biotechnology company Phrontline Biopharma, supporting the development of next-generation antibody-drug conjugates (ADCs).
news
Oral arginine reduces harmful amyloid in Alzheimer’s models
A naturally occurring amino acid commonly found in supplements has reduced harmful amyloid build-up and eased symptoms in animal models of Alzheimer’s disease.
news
DeepTarget tool helps identify secondary cancer drug targets
A new computational tool, DeepTarget, is demonstrating context-specific targets and repurposing opportunities, showing that what may be a side effect in one patient could serve as a treatment in another.
